News
Premier, Inc. to Participate in Piper Sandler 34th Annual Healthcare Conference on November 30, 2022
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. William Doyle, Novocure’s Executive Chairman, and Ashley
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of an employee inducement award.
On November 21, 2022
Pharnext: completion of the reverse split of its shares on the basis of 1 new share for 5,000 old shares, start of trading of the shares resulting from the reverse split, and capital reductions
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that Matt Dolan, Executive Vice President, Strategy, Corporate Development and Dexcom Labs, will present an update on the company at the Piper Sandler
EQS-News: Vita 34 benefits from increasing normalization in its core business in the third quarter
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
Mehr Forschung und Überwachung im Kampf gegen weltweiten Affenpocken-Ausbruch: QIAGEN bringt neuen Test für NeuMoDx-Plattform auf den Markt
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) bringt einen neuen Affenpocken-Test für seine automatisierte PCR-basierte NeuMoDx-Plattform auf den Markt. Mit dem Test sollen Forschung und
QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the monkeypox (MPXV) test for its NeuMoDx automated PCR platform to strengthen surveillance and research into
Agilent Reports Fourth-Quarter and Fiscal Year 2022 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.85 billion for the fourth quarter ended Oct. 31, 2022, an increase of 11% compared to the fourth quarter of 2021 and up 17% on a
Acadia Healthcare to Host Investor Day
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will host its first Investor Day on Wednesday, December 7, 2022, in New York City.
The presentation and Q&A session
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase
CONDOR TECHNOLOGIES KÜNDIGT VORSCHLAG AN
Condor Technologies NV (EURONEXT: MLMFI ISIN: BE6252013725), gibt bekannt, dass der Vorstand am November 18, 2022 beschlossen hat der Hauptversammlung vorzuschlagen, die Aktien der Condor
Condor Technologies Announces Proposal
Condor Technologies NV (EURONEXT: MLMFI ISIN: BE6252013725), announces that, on November 18 th.2022, its board of directors has decided to propose to the general shareholders’ meeting to split the
EQS-News: Burcon JV, Merit Functional Foods and Canadian Partners to Develop New Line of Plant-based Seafood Alternatives
Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced that it will host a live webcast on
MD Medical Group Investments Plc: MD Medical Group opens new clinic in Yekaterinburg
EQS-News: Burcon to Present at the Canaccord Genuity AgriFood Tech Innovation Virtual Forum